A

ll the recent rancor over drug pricing has led biotech to change its ways. Not by making new drugs cheaper, of course, but by holding off on naming a price — and thus inviting controversy — until the last possible minute.

Nowadays, as soon as a drug wins Food and Drug Administration approval, so begins a debate about whether it’s worth the thousands of dollars a year new therapies generally cost. And so companies, perhaps mindful of how a few scolding tweets can snowball into a market-moving event, are starting to keep that information under wraps for as long as possible.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.